TC
OVID icon

Tejara Capital’s Ovid Therapeutics OVID Stock Holding History

Tejara Capital’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-29,329
Closed -$34.6K – 67
2024
Q3 		$34.6K Sell
29,329
-39,188
-57% -$40.9K 0.02% 54
2024
Q2 		$52.7K Sell
68,517
-4,636
-6% -$12.9K 0.02% 67
2024
Q1 		$223K Hold
73,153
– – 0.08% 71
2023
Q4 		$236K Buy
+73,153
New +$250K 0.1% 63
2023
Q3 		– Sell
-112,591
Closed -$369K – 73
2023
Q2 		$369K Sell
112,591
-6,200
-5% -$21.1K 0.18% 64
2023
Q1 		$306K Buy
118,791
+11,300
+11% +$26.8K 0.16% 68
2022
Q4 		$200K Buy
+107,491
New +$183K 0.12% 87

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Tejara Capital's OVID Position: Q4 2024 in Review

Tejara Capital sold out of Ovid Therapeutics (OVID) in Q4 2024, closing a stake of 29,329 shares — an estimated $34.6K sold.

Tejara Capital first reported a position in OVID in Q4 2022 and held it in 7 quarters. The position peaked at $369K in Q2 2023. 82 funds tracked by Wall St. Rank hold OVID as of Q4 2024.

  • Tejara Capital reported no remaining Ovid Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Tejara Capital sold 29,329 Ovid Therapeutics shares in Q4 2024, an estimated $34.6K.
  • Tejara Capital first reported a position in Ovid Therapeutics in Q4 2022 and held it in 7 quarters.
  • Tejara Capital's Ovid Therapeutics position peaked at $369K in Q2 2023.
  • 82 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2024.

Based on Tejara Capital's 13F filing for Q4 2024, filed 10 Feb 2025.